Most currently available antidepressants target monoamine neurotransmitter function.
However, a purely neurotransmitter-based explanation for antidepressant drug action is …

The study of animal emotion, as with its human equivalent, can be confusing due to the
complicated and inconsistent use of terminology, and the number of interlinked fields and …

Depression is a leading cause of disability worldwide and improving its treatment is a core
research priority for future programmes. A change in the view of psychological and …

Selective serotonin reuptake inhibitors (SSRIs) constitute a first-line antidepressant
intervention, though the precise cognitive and computational mechanisms that explain …

The ability of the N-methyl-d-aspartate receptor antagonist ketamine to induce a rapid and
sustained antidepressant effect has led to a surge in pre-clinical studies investigating …

BackgroundMood and anxiety disorders are ubiquitous but current treatment options are
ineffective for many sufferers. Moreover, a number of promising pre-clinical interventions …

Anhedonia, a pronounced reduction in interest or pleasure in any of life's daily activities, is a
cardinal symptom of major depression. In this Perspective article, we synthesise the recent …

Mood disorders represent one of society's most costly and challenging health burdens. The
drug treatments used today were initially discovered serendipitously in the 1950s. Animal …

The stress response comprises a phylogenetically conserved set of cognitive, physiological,
and behavioral responses that evolved as a survival strategy. In this context, the memory of …

Major depressive disorder is a leading global cause of disability. There is a growing interest
for memory in mood disorders since it might constitute an original tool for prevention …